Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms

The Members of the WFSBP Task Force on Biological Markers

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Objectives: Despite progress in identifying molecular pathophysiological processes in schizophrenia, valid biomarkers are lacking for both the disease and treatment response. Methods: This comprehensive review summarises recent efforts to identify molecular mechanisms on the level of protein and gene expression and epigenetics, including DNA methylation, histone modifications and micro RNA expression. Furthermore, it summarises recent findings of alterations in lipid mediators and highlights inflammatory processes. The potential that this research will identify biomarkers of schizophrenia is discussed. Results: Recent studies have not identified clear biomarkers for schizophrenia. Although several molecular pathways have emerged as potential candidates for future research, a complete understanding of these metabolic pathways is required to reveal better treatment modalities for this disabling condition. Conclusions: Large longitudinal cohort studies are essential that pair a thorough phenotypic and clinical evaluation for example with gene expression and proteome analysis in blood at multiple time points. This approach might identify biomarkers that allow patients to be stratified according to treatment response and ideally also allow treatment response to be predicted. Improved knowledge of molecular pathways and epigenetic mechanisms, including their potential association with environmental influences, will facilitate the discovery of biomarkers that could ultimately be effective tools in clinical practice.

Original languageEnglish
Pages (from-to)330-356
Number of pages27
JournalWorld Journal of Biological Psychiatry
Volume18
Issue number5
DOIs
Publication statusPublished - 2017 Jul 4

Fingerprint

Endophenotypes
Advisory Committees
Schizophrenia
Consensus
Biomarkers
Epigenomics
Histone Code
Gene Expression
DNA Methylation
Proteome
Therapeutics
Metabolic Networks and Pathways
MicroRNAs
Longitudinal Studies
Cohort Studies
Lipids
Research
Proteins

Keywords

  • biomarkers
  • epigenetics
  • lipids
  • proteomics
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Consensus paper of the WFSBP Task Force on Biological Markers : Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. / The Members of the WFSBP Task Force on Biological Markers.

In: World Journal of Biological Psychiatry, Vol. 18, No. 5, 04.07.2017, p. 330-356.

Research output: Contribution to journalReview article

@article{4dcc6152933b43d681fb33ee4f2aa924,
title = "Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms",
abstract = "Objectives: Despite progress in identifying molecular pathophysiological processes in schizophrenia, valid biomarkers are lacking for both the disease and treatment response. Methods: This comprehensive review summarises recent efforts to identify molecular mechanisms on the level of protein and gene expression and epigenetics, including DNA methylation, histone modifications and micro RNA expression. Furthermore, it summarises recent findings of alterations in lipid mediators and highlights inflammatory processes. The potential that this research will identify biomarkers of schizophrenia is discussed. Results: Recent studies have not identified clear biomarkers for schizophrenia. Although several molecular pathways have emerged as potential candidates for future research, a complete understanding of these metabolic pathways is required to reveal better treatment modalities for this disabling condition. Conclusions: Large longitudinal cohort studies are essential that pair a thorough phenotypic and clinical evaluation for example with gene expression and proteome analysis in blood at multiple time points. This approach might identify biomarkers that allow patients to be stratified according to treatment response and ideally also allow treatment response to be predicted. Improved knowledge of molecular pathways and epigenetic mechanisms, including their potential association with environmental influences, will facilitate the discovery of biomarkers that could ultimately be effective tools in clinical practice.",
keywords = "biomarkers, epigenetics, lipids, proteomics, Schizophrenia",
author = "{The Members of the WFSBP Task Force on Biological Markers} and Andrea Schmitt and Daniel Martins-de-Souza and Schahram Akbarian and Cassoli, {Juliana S.} and Hannelore Ehrenreich and Andre Fischer and Alfred Fonteh and Gattaz, {Wagner F.} and Michael Gawlik and Manfred Gerlach and Edna Gr{\"u}nblatt and Tobias Halene and Alkomiet Hasan and Kenij Hashimoto and Kim, {Yong Ku} and Kirchner, {Sophie Kathrin} and Johannes Kornhuber and Kraus, {Theo F.J.} and Berend Malchow and Nascimento, {Juliana M.} and Moritz Rossner and Markus Schwarz and Johann Steiner and Leda Talib and Florence Thibaut and Peter Riederer and Peter Falkai",
year = "2017",
month = "7",
day = "4",
doi = "10.1080/15622975.2016.1224929",
language = "English",
volume = "18",
pages = "330--356",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Consensus paper of the WFSBP Task Force on Biological Markers

T2 - Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms

AU - The Members of the WFSBP Task Force on Biological Markers

AU - Schmitt, Andrea

AU - Martins-de-Souza, Daniel

AU - Akbarian, Schahram

AU - Cassoli, Juliana S.

AU - Ehrenreich, Hannelore

AU - Fischer, Andre

AU - Fonteh, Alfred

AU - Gattaz, Wagner F.

AU - Gawlik, Michael

AU - Gerlach, Manfred

AU - Grünblatt, Edna

AU - Halene, Tobias

AU - Hasan, Alkomiet

AU - Hashimoto, Kenij

AU - Kim, Yong Ku

AU - Kirchner, Sophie Kathrin

AU - Kornhuber, Johannes

AU - Kraus, Theo F.J.

AU - Malchow, Berend

AU - Nascimento, Juliana M.

AU - Rossner, Moritz

AU - Schwarz, Markus

AU - Steiner, Johann

AU - Talib, Leda

AU - Thibaut, Florence

AU - Riederer, Peter

AU - Falkai, Peter

PY - 2017/7/4

Y1 - 2017/7/4

N2 - Objectives: Despite progress in identifying molecular pathophysiological processes in schizophrenia, valid biomarkers are lacking for both the disease and treatment response. Methods: This comprehensive review summarises recent efforts to identify molecular mechanisms on the level of protein and gene expression and epigenetics, including DNA methylation, histone modifications and micro RNA expression. Furthermore, it summarises recent findings of alterations in lipid mediators and highlights inflammatory processes. The potential that this research will identify biomarkers of schizophrenia is discussed. Results: Recent studies have not identified clear biomarkers for schizophrenia. Although several molecular pathways have emerged as potential candidates for future research, a complete understanding of these metabolic pathways is required to reveal better treatment modalities for this disabling condition. Conclusions: Large longitudinal cohort studies are essential that pair a thorough phenotypic and clinical evaluation for example with gene expression and proteome analysis in blood at multiple time points. This approach might identify biomarkers that allow patients to be stratified according to treatment response and ideally also allow treatment response to be predicted. Improved knowledge of molecular pathways and epigenetic mechanisms, including their potential association with environmental influences, will facilitate the discovery of biomarkers that could ultimately be effective tools in clinical practice.

AB - Objectives: Despite progress in identifying molecular pathophysiological processes in schizophrenia, valid biomarkers are lacking for both the disease and treatment response. Methods: This comprehensive review summarises recent efforts to identify molecular mechanisms on the level of protein and gene expression and epigenetics, including DNA methylation, histone modifications and micro RNA expression. Furthermore, it summarises recent findings of alterations in lipid mediators and highlights inflammatory processes. The potential that this research will identify biomarkers of schizophrenia is discussed. Results: Recent studies have not identified clear biomarkers for schizophrenia. Although several molecular pathways have emerged as potential candidates for future research, a complete understanding of these metabolic pathways is required to reveal better treatment modalities for this disabling condition. Conclusions: Large longitudinal cohort studies are essential that pair a thorough phenotypic and clinical evaluation for example with gene expression and proteome analysis in blood at multiple time points. This approach might identify biomarkers that allow patients to be stratified according to treatment response and ideally also allow treatment response to be predicted. Improved knowledge of molecular pathways and epigenetic mechanisms, including their potential association with environmental influences, will facilitate the discovery of biomarkers that could ultimately be effective tools in clinical practice.

KW - biomarkers

KW - epigenetics

KW - lipids

KW - proteomics

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84992417466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992417466&partnerID=8YFLogxK

U2 - 10.1080/15622975.2016.1224929

DO - 10.1080/15622975.2016.1224929

M3 - Review article

C2 - 27782767

AN - SCOPUS:84992417466

VL - 18

SP - 330

EP - 356

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 5

ER -